The net loss for the quarter ended June 30, 2009 was $11.3 million compared with a net loss of $13.2 million for the same period in 2008.

Revenue for the second quarter of 2009 was $3.8 million compared to $3.0 million for the same period in 2008. Revenues included net sales of FARESTON?® (toremifene citrate) 60 mg, marketed for the treatment of metastatic breast cancer in postmenopausal women, and collaboration revenue from our collaborations with Ipsen Developments Limited and Merck & Co., Inc. Net sales of FARESTON?® were $949,000 and $274,000 for the three months ended June 30, 2009 and 2008, respectively. Collaboration revenue was $2.9 million and $2.7 million for the second quarter of 2009 and 2008, respectively.

For the three months ended June 30, 2009 and 2008, research and development expenses were $7.7 million and $10.4 million, respectively. General and administrative expenses increased during the three months ended June 30, 2009 to $6.9 million from $6.4 million for the three months ended June 30, 2008.

At June 30, 2009 GTx had cash, cash equivalents and short-term investments of $68.9 million. GTx has no debt and no warrants.

Conference Call

There will be a conference call today at 9 a.m. Eastern Time to discuss GTx??™s second quarter financial results and to provide a company update. To listen to the conference call, please dial:

866-711-8198 from the United States and Canada or 617-597-5327 (International)The access code for the call is 56156529.

A playback of the call will be available beginning today at 11:00 a.m. Eastern Time through August 24, and may be accessed by dialing:

888-286-8010 from the United States and Canada or 617-801-6888 (International)The reservation number for the replay is 77179556.

gtxinc